View More Recent Stories

Jan 11, 2021 08:00AM Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
Jan 5, 2021 08:00AM Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 7, 2020 08:00AM Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin
Dec 4, 2020 08:03AM Magenta Therapeutics (MGTA), bluebird bio Inc. (BLUE) Report Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145
Dec 4, 2020 08:00AM Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Ce
Nov 9, 2020 08:09AM Magenta Therapeutics (MGTA) Appoints Steve Mahoney as Chief Financial and Operating Officer
Nov 9, 2020 08:00AM Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
Nov 5, 2020 08:00AM Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
Nov 4, 2020 11:02AM Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
Sep 11, 2020 08:00AM Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September
Sep 2, 2020 12:00PM Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
Sep 2, 2020 08:00AM Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operati
Aug 31, 2020 08:00AM Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual
Aug 6, 2020 08:00AM Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
Aug 3, 2020 04:05PM Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
Jun 15, 2020 06:03AM Magenta Therapeutics (MGTA), Beam Therapeutics (BEAM) Enter Collaboration to Evaluate Targeted Antibody-Drug Conjugate MGTA-117 as Conditioning Regimen for Base Editing Therapies
Jun 15, 2020 06:00AM Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies
Jun 11, 2020 07:02AM Magenta Therapeutics (MGTA) Reports Collaboration with National Marrow Donor Program/Be The Match to Advance Development of MGTA-145
Jun 11, 2020 07:00AM Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Su
Jun 8, 2020 04:30PM Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
May 7, 2020 07:30AM Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
May 6, 2020 07:17AM AVROBIO, Inc (AVRO), Magenta Therapeutics (MGTA) Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
May 6, 2020 07:00AM Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
May 6, 2020 07:00AM AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
Apr 30, 2020 08:00AM Magenta Therapeutics to Host Business Update Conference Call
Apr 28, 2020 04:30PM Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Apr 17, 2020 08:11AM Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
Apr 16, 2020 08:03AM Magenta Therapeutics (MGTA) Provides Business Update Related to COVID-19 Pandemic
Apr 16, 2020 08:00AM Magenta Therapeutics Provides Business Update
Feb 26, 2020 08:30AM Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston
Feb 6, 2020 08:30AM Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City
Feb 5, 2020 08:30AM Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing
Jan 6, 2020 08:30AM Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco
Dec 9, 2019 07:46AM Magenta Therapeutics (MGTA) Announces Successful Gene Therapy Transplant Without Chemotherapy in Primates Using Single Dose of Antibody-drug Conjugate
Dec 9, 2019 07:45AM Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
Dec 7, 2019 05:30PM First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
View More Recent Stories